Which lung cancer patients is Sotorasib mainly suitable for?

Sotorasib is an oral small molecule inhibitor that targets KRAS G12C mutations. It is the world's first targeted drug approved for the treatment of KRAS G12C mutation-related non-small cell lung cancer (NSCLC). KRASThe gene is one of the most common oncogenes in lung cancer, and the G12C mutation is one of the common subtypes. The incidence rate in patients with non-small cell lung cancer is about 13%, especially in patients with a long smoking history. KRAS has long been considered an “undruggable” target. The launch of sotorasibu has broken through this technical problem.

This drug is mainly suitable for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed after receiving at least one systemic treatment (such as chemotherapy or immunotherapy)KRAS G12C mutation. In this group of people, the therapeutic effect of sotoracib is obvious. Clinical research data shows that its objective response rate (ORR) is about 37%. Most patients can achieve disease control, and some patients even experience tumor shrinkage and remission. This result provides a new treatment option for patients with KRAS mutations who previously lacked effective targeted treatment options.

Sotoracib has good oral bioavailability, convenient administration, and is well tolerated in most patients. Common adverse reactions include diarrhea, nausea, fatigue and increased liver function indicators, which are usually mild to moderate. A few patients may experience severe liver toxicity, so liver function needs to be monitored regularly during treatment. Compared with traditional chemotherapy, its side effect spectrum is more controllable, its quality of life is less affected, and it is more suitable for patients with advanced lung cancer who require long-term management.

To sum up, sotorasiib is a targeted drug specifically used to treat KRAS G12C mutation-positive non-small cell lung cancer patients, and is especially suitable for patients who have failed previous treatments. With the development of precision medicine and the popularization of KRAS testing, sotorasib will be more widely used, bringing significant clinical benefits and new treatment hope to lung cancer patients who were once considered a "targetless" population.

Reference materials:https://www.lumakras.com/